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Endometrial cancer is the most 
common gynecological cancer and 
the fourth most common cancer in 
women worldwide. In spite of its’ 
relative importance to overall 
morbidity among women, molecular 
research in endometrial cancers lags 
far behind other cancers such as 
breast and colorectal. Nowhere is 
this more true than in research in the 
newly emergent field of post-
transcriptional gene regulation by 
small, regulatory RNAs, primarily 
microRNAs (miRNAs). Here, 
structure, biogenesis, and mode of 
action of miRNAs are presented 
along with a brief overview of the 
role of miRNAs in carcinogenesis 
and a review of the few miRNA 
studies in endometrial cancer carried 
out to date. 
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In a now classic review paper, 
Hanahan and Weinberg1 outlined 
what they considered to be the 
hallmarks of cancer. These 
hallmarks, that are acquired by 
cancer cells, are 1. self-sufficiency in 
growth signals, the ability of cancer 
cells to promote their own growth, 2. 
insensitivity to anti-growth signals, 
the ability of cancer cells to ignore 
homeostatic signals, 3. evasion of 
apoptosis, the ability of cancer cells 
to ignore programmed cell death, 4. 
limitless replicative potential, the 
ability of cancer cells to grow 
unchecked, 5. sustained 
angiogenesis, the ability of cancer 
cells to supply themselves with 
resources such as oxygen and 
nutrients, and 6. tissue invasion and 
metastasis, the ability of cancer cells 
to colonize other regions of the body. 
Not all cancer cells will acquire these 
characteristics at the same rate nor 
will they acquire them in the same 
order nor will they acquire them by 
the same mechanisms thus making 
cancers a very heterogenous group 
of diseases with individual and quite 
variable characteristics. However, 
from the list of acquired 
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characteristics presented above it is 
abundantly clear that the one thing 
that cancer cells do have in common 
from the very beginning is that they 
do not behave the same way that 
non-cancer cells do. 
 
Normal cells, whether they be skin 
cells, neurons, kidney, or uterus, 
maintain their individual integrity, 
respond to their micro- and macro-
environments, and interact with other 
cells according to a set of internally 
and externally driven programs 
designed to sustain equilibria that 
were established over more than 
three billion years of evolution. 
Cancer cells seem not to obey many 
of these rules, they create their own 
set of programs that ignore the 
established principles of cellular 
response and interaction. They are, 
in essence, an invasive species for 
which the equilibria of the 
environment in which they find 
themselves are irrelevant. Yet, 
cancer cells are not aliens that 
dropped in from an alternate 
universe. Indeed, cancer cells are 
ultimately all descended from 
perfectly normal cells that obeyed all 
of the rules. Thus, the rules that 
cancer cells follow are not written de 
novo but are, rather, re-written from 
the normal rules. 
 
The rules of cellular behavior are 
enforced by a single primary agency. 
Most of the actions and reactions 
carried out in any cell are 
implemented by proteins. Cellular 
proteins are present in the cells in a 
bewildering array of sizes, functions, 
and amounts yet all of these proteins 
ultimately arise from the primary 
messages carried in the genes. The 
DNA sequences that encode the 
proteins are first transcribed into an 
RNA message which is, in turn, 
translated into the specific amino 
acid sequence of a protein and this 
is done in a carefully managed 
amount necessary for the cell to 
function. The checks and balances 
on the amounts of the various 
proteins required for a specific cell to 
function reside at three levels. At the 
DNA level there are elegant feed 
back systems that determine the 
time, the place, and the amount of 
transcription of genomic DNA into 
RNA. At the protein level there is an 
equally elegant system in which the 
primary amino acid sequences of 
proteins are processed into mature 
proteins able to carry out their 
specific functions. This is 
accompanied by cell- and tissue-
specific mechanisms for protein 
transport as well as protein-protein 
and protein-RNA interactions. Until 
recently, it was believed that these 
two levels of control were all that the 
cell had at its disposal. In the past 
few years we have become aware of 
a level of control that lies in between 
the two we knew. This began in 1993 
in the laboratory of Victor Ambros 
with the chance discovery in the tiny 
worm Caenorhabtidis elegans of a 
very short RNA sequence that, 
instead of coding for a protein, was 
capable of regulating the translation 
of the messenger RNA of another 
gene into its protein. This was a 
completely unknown level of control, 
now called post-transcriptional gene 
regulation, which has been found to 
be a ubiquitous and powerful 
mechanism throughout both the 
animal and plant kingdoms. In 
human and other animal cells, the 
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primary agent of this post-
transcriptional gene regulation is the 
microRNA (miRNA). Here, we 
present the structure, biosynthesis, 
and mechanism of action of miRNAs, 
discuss the current level of 
understanding of the role of miRNA-
directed gene regulation in cancer, 
and, finally, the status of miRNA 
research in endometrial cancers. 
 
miRNA structure, biosynthesis, 
and mode of action 
           
The discovery of  miRNAs and the 
subsequent discovery of other small 
regulatory RNAs represent an 
entirely new arena in functional 
genomics involving the regulation of 
gene expression following DNA to 
RNA transcription. Since the first 
miRNA was identified in 19932,3, 
thousands of these tiny (21-24nt) 
regulatory elements have been 
identified throughout the plant and 
animal kingdoms as well as in a 
number of viruses4. Recognition of 
the role of small regulatory RNAs in 
post-transcriptionally regulating 
genes involved in a host of cellular 
processes, including cellular 
differentiation, development, and 
apoptosis as well as pathogenesis, 
continues to expand5,6. One 
important aspect of this growing 
recognition of the role of small 
regulatory RNAs in cellular 
processes is that they themselves 
are precisely regulated through as 
yet unknown processes. It is clear, 
however, that small regulatory RNA 
expression varies enormously by 
tissue type, developmental stage, 
and by factors such as disease and 
external environmental stressors. 
Thus, the small RNA profile of any 
cell in any species at any particular 
stage of development or 
circumstance cannot be predicted 
but, rather, must be empirically 
determined. Moreover, it has 
become apparent that one miRNA 
can regulate the translation of many 
genes, that any one gene can be 
post-transcriptionally regulated by 
more than one miRNA, and that the 
specific mechanisms of 
miRNA/target mRNA interactions are 
complex well beyond simple 
antisense base-pair binding7-9.  
 
MicroRNA biogenesis (figure 1) 
begins with the RNA polymerase II 
directed production of a primary RNA 
transcript (pri-miRNA) that can be 
several thousands of nucleotides in 
length and be either intragenic, lying 
in the DNA between genes, or 
intronic, lying in the non-coding DNA 
within genes. Primary miRNA 
transcripts are capped and 
polyadenylated in the same way as 
protein coding mRNA transcripts10. 
The pri-miRNA transcript contains 
within it one (usually) or more 
(rarely) sequences that form 
characteristic thermodynamically 
stable hairpin structures. This hairpin 
structure, called the precursor or pre-
miRNA, typically ranges in size from 
60nt to 110nt (figure 1). These 
hairpin structures induce the 
formation of an RNA-protein 
complex, composed of the RNA 
hairpin, the RNase III endonuclease 
DROSHA, and a double-stranded 
RNA binding protein partner which in 
mammals is called DGCR8 11. The 
latter protein binds the pre-miRNA 
and DROSHA excises it from the 
primary transcript. The remaining 
RNA in the pri-miRNA transcript is 
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simply recycled in the nucleus. Once 
excised, the pre-miRNA is handed 
off to another nuclear protein, a Ran 
transport receptor protein family 
member called Exportin 5, which 
binds the hairpin and transports it 




Figure 1. The pathway of microRNA biogenesis. A primary RNA transcript is generated by RNA 
polII which then capped and polyadenylated (pri-miRNA). Within this transcript a 
thermodynamically stable hairpin structure is formed (pre-miRNA). The hairpin structure is 
excised from the primary transcript through the combined action of the enzyme DROSHA and its 
partner DGCR8. This hairpin is passed off to a transport protein, Exportin 5, which ferries the 
hairpin from the nucleus to the cytoplasm. Once in the cytoplasm, the hairpin is bound by the 
enzyme Dicer and its partner TRBP which excises the small double-stranded RNA containing the 
mature miRNA and the star sequence. This is then handed off to an Argonaute protein, Ago2, 
which selects the mature miRNA strand and packages it into the RNA-induced silencing complex, 
RISC, for transport to its eventual mRNA target. 
 
In the cytoplasm the pre-miRNA 
hairpin is recognized as a double-
stranded RNA which induces a 
second RNase III endonuclease, 
called Dicer, which binds to the 
hairpin in association with another 
protein called TRBP (TAR RNA 
binding protein) and cleaves it in a 
precise manner to produce a small 
(21nt – 23nt) double-stranded 
molecule which is composed of the 
mature miRNA effector and its 
complement called the star, or 
miRNA*, sequence13,14. 
Conventional nomenclature refers to 
a microRNA as miR. This is 
preceded by the species from which 
it comes, for example Hsa for Homo 
sapiens, Mmu for the mouse species 
Mus musculus, and Cfa for the dog 
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Canis familiaris. It is then followed by 
a number that is assigned by the 
curatorial miRNA database, 
miRBase, at the University of 
Manchester in the United Kingdom4. 
Many miRNAs are found in multiple 
species and some are quite ancient 
so such a nomenclature avoids a 
great deal of confusion. In practice, 
however, most miRNA are simply 
referred to as miR-xxx and they will 
be in this paper with the 
understanding that, for example, the 
designation miR-21 or miR-200c 
actually refers to hsa-miR-21 or hsa-
miR-200c. 
  
The double-stranded RNA generated 
by Dicer/TRBP is nearly always 
imperfectly complementary, with one 
or more mismatched bases being the 
rule, and displays a 2nt 3’ overhang 
on both strands (figure 1). This 
double-stranded molecule is then 
handed off to an Argonaute protein, 
called AGO2 in mammals, which is 
the primary component of a 
ribonucleoprotein complex called 
RISC (RNA induced silencing 
complex). In RISC the AGO2 protein 
selects the mature miRNA strand 
and cleaves the star strand. At this 
point, RISC transports the mature 
miRNA sequence to its target 
mRNA. Mature miRNAs bind in an 
antisense orientation to one or more 
locations in the 3’ UTR of the mRNA 
where the result is either to suppress 
(usually) or eliminate (rarely) mRNA 
translation into an amino acid 
sequence. Complementarity of the 
mature miRNA sequence to its 
mRNA target sequence is nearly 
always imperfect. Indeed, it is 
believed that the mismatches in the 
miRNA/mRNA complementary 
sequences are necessary. There is 
one piece of the miRNA sequence 
that is quite specific, however. The 
8nt RNA sequence from position two 
through position nine from the 5’ end 
is called the seed and it is the seed 
that principally determines 
recognition of the miRNA and its 
mRNA target5,8. It is through this 
mechanism that cells can regulate 
protein production even if the original 
DNA encoding that protein is fully 
transcribed into RNA. 
 
miRNAs and Cancer: Oncogenes 
and Suppressors 
 
The rapidly expanding role of 
miRNAs in cancer has been 
documented in a number of excellent 
recent reviews15-17. What is clear 
from these and other reviews is that 
miRNAs can function as both tumor 
suppressors and as oncogenes 
depending upon their targets. There 
are currently more than 700 human 
microRNAs archived in miRBase. Of 
these, only a handful have yet to be 
fully evaluated for their potential 
involvement in cancer. However, 
Calin et al.18 showed that more than 
half of the then known human 
miRNAs were located in cancer-
associated genome regions or in 
fragile sites. Over the past few years, 
a number of specific human miRNAs 
have been shown to be differentially 
expressed in specific cancers. For 
example, Ciafre et al.19 showed that 
several miRNAs (notably miR-21, 
miR-221, and miR-181) are 
significantly over- or under-
expressed in primary glioblastoma. 
Other examples include differential 
expression of miR-15 and miR-16 in 
CLL20, a number of miRNAs in 
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hepatocellular carcinoma21, let-7 and 
the miR-17-92 cluster in lung 
cancer22,23, miR-155 and the miR-17-
92 cluster in lymphomas24,25; a large 
number of miRNAs in clear cell renal 
cell cancers26 and numerous 
miRNAs in GI cancer27.  
 
A very nice compilation of the most 
recent findings regarding specific 
miRNAs was presented by Spizzo et 
al.28. They note that the functional 
consequences of substantial 
changes in the expression of 
miRNAs, either up or down relative 
to non-cancer cells, are only just 
starting to come to light. 
Overexpression of the miRNA miR-
21 can induce self-sustaining growth 
signals in cells, the first hallmark of 
cancer proposed by Hanahan and 
Weinberg1 as discussed above. 
Insensitivity to anti-growth signals, 
the second hallmark of cancer, has 
been achieved through inhibition of 
E2F transcription factors in response 
to overexpression of the miR-17 
miRNA cluster on human 
chromosome 13q31.1 as well as 
through overexpression of the miR-
106b-25 cluster located on human 
chromosome 7q22.1. Spizzo et al. 
note that specific E2F growth factors 
are inhibited by specific members of 
these miRNA clusters, for example 
E2F2 and E2F3 are inhibited by miR-
20a, a member of the miR-17 
cluster, and expression of E2F1 is 
inhibited by both miR-17-5p and 
miR-20a from the miR-17 cluster and 
by miR-106b and miR-92 of the miR-
106b cluster. Alteration of apoptosis 
pathways potentially leading to 
evasion can be achieved through 
miRNAs targeting either anti-
apoptotic proteins, such as BCL2 
and MCL1 by the miR-15/16 cluster, 
or pro-apoptotic proteins, such as 
TP53BP1 by miR-155. Unrestricted 
proliferation can be induced through 
down-regulation of miR-138 which 
leads to repressed translation of 
telomerase reverse transcriptase or 
TERT. Sustained angiogenesis is 
well known to be directly caused by 
hypoxia and the hypoxia-inducible 
factor, HIF-1, which, in turn, 
activates several miRNAs including 
miR-30b, miR-93, miR-181b, and, in 
particular, miR-210. 
 
As noted, whether or not a specific 
miRNA acts as a suppressor or as 
an oncogene relates to the target, or 
targets, of that miRNA.  As a 
consequence of target specificity and 
the regulatory mechanisms involved, 
a miRNA can be an oncogene in one 
tumor and a tumor suppressor in 
another28. Two genes, HER2 and 
HER3, significantly associated with 
breast cancer survival, are 
suppressed by one of the human 
miR-125 family29 but both miR-125a 
and miR-125b target other genes 
where their effects are likely to be 
oncogenic. The previously 
mentioned miR-17-92 polycistronic 
miRNA cluster on human 
chromosome 13q31.3 has been 
implicated as oncogenic in a number 
of cancers30 but miR-17 has an anti-
tumorigenic effect in breast cancer. 
Other such Jekyll and Hyde miRNAs 
include members of the let-7 family 
and the miR-29 family. Clearly, the 
role of miRNAs in cancer is and will 
continue to be diverse and as 
unpredictable as the genes they 
target. 
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Figure 2. The miRNA landscape of endometrial cancer. microRNAs reported to be over-expressed in 
endometrial cancers compared to normal endometrium are shown as black squares while those reported to 
be under-expressed in endometrial cancers compared to normal endometrium are shown as grey squares. 
The eight miRNAs reported in at least three of the four surveys are bolded. The four extant miRNA surveys 
are; H (Hiroki et al., 2009), B (Boren et al., 2008), C (Chung et al., 2009), W (Wu et al., 2009).  
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MicroRNAs in Endometrial Cancer 
 
It is not by accident or omission that 
the discussion of the state of 
knowledge of the role of miRNAs in 
cancer presented above did not 
include a single mention of 
endometrial cancer. Endometrial 
cancer is the fourth most common 
cancer among women worldwide31,32 
and endometrioid adenocarcinoma 
accounts for 75%-80% of all 
endometrial cancers33 yet 
examination of miRNAs in these 
cancers is minimal in comparison to 
other cancers.  
 
In the first reported survey, Boren et 
al.34 examined expression of 335 
human miRNAs using a hybridization 
array strategy followed by qPCR 
validation of selected candidates on 
the basis of expression levels. Their 
study sample consisted of 61fresh 
frozen endometrial tissues which 
included 37 endometrial cancers, 20 
normal endometrium, and four 
atypical hyperplasias. They were 
able to identify a total of thirteen 
miRNAs as either significantly over-
expressed or significantly under-
expressed in endometrial cancers as 
compared to normal endometrium. 
Their eight over-expressed miRNAs 
were let-7c, miR-103, miR-106a, 
miR-107, miR-181a, miR-185, miR-
210 and miR-423 and their five 
under-expressed miRNAs were let-
7i, miR-30c, miR-152, miR-193, and 
miR-221. In addition to the miRNAs, 
Boren et al. assessed expression 
levels of 22,000 messenger RNAs 
again using a hybridization array 
strategy. Ninety mRNAs were seen 
to be differentially expressed in 
endometrial cancers compared with 
normal endometrium and, with both 
sets of expression levels in hand, 
they were able to link twenty-six 
differentially expressed mRNAs to 
their differentially expressed miRNAs 
by confirming that the mRNAs were 
predicted targets of one or more of 
the miRNAs. These miRNA::mRNA 
pairings have, as yet, to be 
experimentally confirmed.  
 
Wu et al.35 employed a similar 
hybridization array strategy to 
assess differential expression among 
469 miRNAs in endometrial cancers. 
Their survey revealed 17 over-
expressed miRNAs and six under-
expressed miRNAs in a sample 
composed of ten endometrioid 
adenocarcinomas each paired with 
normal endometrium from the same 
patients. In addition, they selected 
six of the 23 miRNAs for subsequent 
qPCR validation. From the 
validations they observed that miR-
205 was eighteen-fold over-
expressed in the cancers and that 
miR-449 and miR-429 were sixteen-
fold and fifteen-fold over-expressed 
respectively. In the opposite 
direction, miR-99b and miR-204 
were seen to be less than 0.3-fold 
expressed in the cancers compared 
to the normal endometrium.  
 
Using a different approach, that of 
direct qPCR assessments of miRNA 
expression levels, Chung et al.36 
surveyed 157 miRNAs in fresh 
frozen tissues composed of 22 
normal endometrium and 30 
endometrioid adenocarcinomas. 
They reported that thirty of the 157 
miRNAs were significantly over-
expressed in the cancers and they 
carried out subsequent validations of 
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fourteen (miR-95, miR-103, miR-
106a, miR-151, miR-155, miR-182, 
miR-183, miR-194, miR-200a, miR-
200c, miR-203, miR-205, and miR-
210). As in the Wu et al. study, the 
most highly over-expressed 
microRNA was miR-205 which, in 
these samples was more than 25-
fold over-expressed in the 
adenocarcinomas than in the normal 
endometrium. Others included miR-
182 (>8-fold), miR-325 (8-fold), and 
miR-183 (7-fold).  
 
The most ambitious miRNA survey in 
endometrial cancer to date was 
recently reported by Hiroki et al.37. 
Using Agilent microRNA 
hybridization arrays they profiled the 
expression levels of 470 miRNAs in 
a sample of seven normal 
endometrium and 21 endometrial 
serous adenocarcinomas. This 
survey identified a total of 66 
microRNAs that were over-
expressed in the cancers compared 
to the normal tissues and 54 that 
were under-expressed in the cancers 
compared to the normal tissues. 
Among these, they chose to qPCR 
validate eight candidate miRNAs that 
were among those seen to be under-
expressed (miR-10b, miR-29b, miR-
34b, miR-101, miR-133a, miR-133b, 
miR-152, and miR-411) and one, 
miR-205, that was very highly over-
expressed (>267-fold) in the cancers 
compared to the normal 
endometrium. 
 
Taking all four extant studies 
together and making allowances for 
differences in the methods used as 
well as the fact that there is no 
information on how much the miRNA 
sets overlapped, comparative 
miRNA expression patterns are 
presented in Figure 2. In spite of the 
limitations of such a comparison it is 
interesting to note that seven 
miRNAs (miR-10a, miR-106a, miR-
182, miR-200a, miR-200c, miR-203, 
and miR-205) are significantly over-
expressed in three of four surveys 
and an eighth, miR-210, is 
significantly over-expressed in all 
four. Several of these miRNAs, 
notably miR-182, miR-205 and miR-
210, are so-called “cancer miRs” in 
that they display significant levels of 
over-expression in numerous 
cancers. In addition, the five 
members of the “200 family,” miR-
200a, miR-200b, and miR-429 on 
human chromosome 1 and miR-200c 
and miR-141 on human 
chromosome 12, are well known to 
be coordinately expressed in 
cancers38. Of these, the one 
microRNA that has been specifically 
studied as a validated candidate 
microRNA in endometrial cancer is 
miR-200c. Cochrane et al.39 
examined the potential involvement 
of miR-200c in endometrial cancer 
from a functional perspective. The 
transcription factors ZEB1 and ZEB2 
(zinc-finger E-box binding homeobox 
1 and 2) are known targets of miR-
200c. ZEB1 is not normally 
expressed in epithelial cells but, 
when inappropriately expressed in 
vitro, it initiates epithelial to 
mesenchyme transition through 
repression of E-cadherin and other 
genes involved in polarity. miR-200c 
is highly expressed in several well-
differentiated cancer cells, such as 
the Ishikawa-H endometrial cancer 
cell line, but displays very low 
expression in poorly differentiated 
cells such as the Hec50co 
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endometrial cancer cell line (see ref 
31 for information on the 
characteristics of these two cell 
lines). This is reflected in similarly 
opposite levels of expression of 
ZEB1 (Ishikawa low / Hec50co high) 
and E-cadherin (Ishikawa high / 
Hec50co negative). Cochrane et al. 
showed that restoration of 
expression of miR-200c in Hec50co 
cells restores E-cadherin expression 
and decreases ZEB1 expression. 
This results in a concomitant decline 
in migration and invasiveness of 
Hec50co cells to levels resembling 
the much less aggressive Ishikawa-
H cells. Thus, miR-200c has been 
confirmed to have a direct influence 
on the behavior of cancer cells.  
 
Another directed miRNA study by 
Huang et al.40 focused on the 
relationship between a specific 
microRNA, miR-129-2, and 
endometrial cancer. The oncogene 
known as the SRY-related high-
mobility group box 4 gene, or SOX4, 
is known to be highly expressed in a 
number of cancers including 
endometrial cancer. Overexpression 
of this gene is related to clinical 
features such as increased 
proliferation and poor outcome. 
Huang et al. (2009) show that 
expression of miR-129-2 is lost in 
endometrial cancers when compared 
to normal endometrium and that 
SOX4 is a validated miR-129-2 
target. When this microRNA was 
transfected into endometrial cancers 
cells, including the afore-mentioned 
Ishikawa H cells, SOX4 expression 
was suppressed as was proliferative 
behavior in these cells. Moreover, 
this effect was also achieved in vitro 
through demethylation reactivation of 
miR-129-2 which led to SOX4 
suppression. This last result 
suggests that hyper-methylation-
mediated silencing of a  microRNA 
leads to derepression of the SOX4 
oncogene. Surprisingly, miR-129-2 
was not reported in any of the four 
miRNA studies discussed here. 
However, as these studies only listed 
miRNAs that displayed significant 
changes in expression levels, there 
is no way to know if miR-129-2 was 
among those examined. 
      
Unlike many other cancers, 
endometrial cancer, along with 
breast, testicular, and cervical 
cancers, is significantly influenced by 
hormones. Cellular growth in the 
human endometrium is controlled by 
the antagonistic effects of estrogen 
and progesterone and endometrial 
carcinogenesis is linked to high 
levels of estrogen not ameliorated by 
the differentiating effects of 
progesterone41. Indeed, it has been 
shown that expression of the two 
progesterone receptor isoforms, 
PRA and PRB, is significantly altered 
in more aggressive endometrial 
cancers and that this has profound 
effects on downstream cellular 
pathways31,41,42. One consequence 
of disrupted progesterone action in 
endometrial cancers is the presence 
of unopposed estrogen. Recently, 
Klinge43 reviewed the effects of 
estradiol, E2, on microRNA 
expression in various human 
cancers. Among the miRNAs whose 
expression was affected by E2 are 
several listed in Figure 2. A few of 
these, let-7c, let-7i, miR-7, miR-23b, 
miR-25, miR-27b, miR-151, miR-
183, miR-195, and miR-423, are 
sporadically reported but four, miR-
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182, miR-200a, miR-200c, and miR-
203, are among those reported in at 
least three of the four miRNA 
surveys. However, the studies cited, 
which focused primarily on breast 
cancers, showed that the effect of E2 
on miRNA expression was cell-type-
dependent. Thus, it remains to be 
seen what effect if any both 
progesterone receptor changes and 
unopposed estrogen might have on 
miRNA expression in endometrial 
cancer.  
 
As noted above, miRNA studies in 
endometrial cancer are few in 
number yet these few studies have 
already identified a number of 
candidate miRNAs for more detailed 
analysis. One of these, miR-200c, 
has proven to be very informative 
with regard to one of the cancer 
hallmarks outlined in the beginning 
of this review- the ability of cancer 
cells to colonize other regions of the 
body. It is this interplay between 
carefully designed miRNA surveys 
and controlled studies of candidates 
identified in those surveys that will 
lead to a much greater 
understanding of the role played by 
small regulatory RNAs in 




At the beginning of this paper it was 
noted that cancer cells behave 
differently than do normal cells and 
that these differences in behavior 
result from cancer cells essentially 
re-writing the rules that apply to 
normal cells existing in equilibrium. 
The principle means that cells use to 
regulate their behavior is through 
appropriate transcription of genes 
into proteins. Cancer cells have been 
shown to reprogram gene 
transcription to their advantage. The 
discovery of microRNAs as a 
complex and powerful post-
transcriptional level of gene 
expression regulation has introduced 
the possibility that cancer cells alter 
miRNA expression to assist in 
carrying out that reprogramming. 
Indeed, it has been suggested that a 
global reduction of miRNA levels is 
emerging as an additional hallmark 
of cancer44. Such global effects can 
be accomplished in a number of 
ways including the activation of 
cancer-associated transcription 
factors like p53 and Myc which are 
known to have direct effects on 
miRNAs of the miR-34 family (p53) 
and miR-17 cluster (Myc). Chang et 
al.45 have further shown that 
activation of Myc in cancer could 
directly reprogram the wider miRNA 
transcriptome. Other potential means 
of accomplishing miRNA 
reprogramming result from the 
massive genetic alterations known to 
occur in cancer cells18,46 and from 
specific alterations of the miRNA 
processing machinery itself47,48. 
Thus, continued detailed studies of 
miRNAs in cancers will shed new 
light on the nature of cellular 
reprogramming and lead to new and 
more efficient ways to attack cancers 
in general44 and, from our 
perspective, endometrial cancers in 
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